论文部分内容阅读
目的:评价地特胰岛素联合格列齐特缓释片治疗继发性磺脲类降糖药失效(SFS)2型糖尿病患者的疗效及安全性。方法:48例SFS 2型糖尿病患者随机分为地特胰岛素联合格列齐特缓释片(D)组和门冬胰岛素30(R)组进行治疗。观察治疗前后两组体质指数(BMI)和糖化血红蛋白(HbAlc)水平,24 h血糖达标时段、24 h平均血糖(MBG)、血糖波动幅度(MAGE)及以及低血糖发生频率及程度等。结果:与治疗前比较,治疗后两组血糖达标时段均明显延长,MBG及HbA1c均明显下降(P<0.05);治疗后两组间低血糖发生率差异无统计学意义(P>0.05),但D组MAGE及低血糖程度均低于R组(P<0.05)。结论:地特胰岛素联合格列齐特缓释片能有效控制SFS的2型糖尿病患者血糖,安全性高。
OBJECTIVE: To evaluate the efficacy and safety of insulin detemir plus gliclazide in the treatment of type 2 diabetes mellitus (T2DM) secondary to sulfonylureas in hypoglycemic agents (SFS). Methods: Forty-eight patients with type 2 diabetes mellitus were randomly assigned to insulin detemir plus gliclazide (D) and insulin aspart 30 (R). The body mass index (BMI) and HbAlc level, the 24 h blood glucose level, the 24 h mean blood glucose (MBG), the blood glucose level (MAGE) and the frequency and degree of hypoglycemia were observed before and after treatment. Results: Compared with those before treatment, the blood glucose levels of both groups were significantly prolonged after treatment, and both MBG and HbA1c were significantly decreased (P <0.05). There was no significant difference in the incidence of hypoglycemia between the two groups after treatment (P> 0.05) However, the levels of MAGE and hypoglycemia in group D were lower than those in group R (P <0.05). Conclusion: Detemir insulin combined with Gliclazide sustained-release tablets can effectively control the blood sugar of SFS patients with type 2 diabetes mellitus, with high safety.